Gomollón Fernando, Santolaria Santos, Sicilia Beatriz, Ferrero Miguel, Revillo María José, Ducóns Julio, Villar Margarita, Celaya María Concepción, Montoro Miguel
Servicio de Aparato Digestivo, Hospital Miguel Servet, Zaragoza, Spain.
Med Clin (Barc). 2004 Oct 16;123(13):481-5. doi: 10.1016/s0025-7753(04)74566-2.
We aimed to assess the resistance of H. pylori to clarithromycin and metronidazole, in patients with and without previous eradication treatment, in a geographic area from the north of Spain. We also analyzed the evolution of resistance rates and its relationships with annual antibiotic consumption.
Retrospective study including all patients with H. pylori infection and positive culture from January 1997 to December 2000. Minimal inhibitory concentrations (MIC) determined by the E test were used to report the clarithromycin (MIC > 2 mg/l) and metronidazole (MIC > 32 mg/l) resistance.
A total of 537 clinical H. pylori isolates from patients without (n = 389) and with previous eradication treatment (n = 148) were studied. H. pylori resistance to clarithromycin and metronidazole was found in 8.7% (95% CI, 6.1-12) and 13.8% (95% CI, 10.4-17.3) patients without previous eradication treatment and in 39.2% (95% CI, 31.3-47.1) and 37.8% (95% CI, 30-45.7) patients with previous eradication treatment (p < 0.001), respectively. Clarithromycin resistance remained stable (1997: 9.7%; 1998: 5.7%; 1999: 11.8%; 2000: 6.2%) whereas metronidazole resistance decreased over the 4 years study period (1997: 38.7%; 1998: 15.1%; 1999: 9%; 2000: 6.9%). We did not observe any clear relationship between resistance's evolution and antibiotic annual consumption.
In our geographic area, primary resistance rates for clarithromycin remained stable whereas resistance for metronidazole decreased over the 4 years period.
我们旨在评估西班牙北部某地区有或无既往根除治疗史的幽门螺杆菌感染患者对克拉霉素和甲硝唑的耐药情况。我们还分析了耐药率的变化及其与年度抗生素消耗量的关系。
回顾性研究纳入了1997年1月至2000年12月期间所有幽门螺杆菌感染且培养阳性的患者。采用E试验测定的最低抑菌浓度(MIC)来报告克拉霉素(MIC>2mg/l)和甲硝唑(MIC>32mg/l)的耐药情况。
共研究了537株来自无既往根除治疗史患者(n = 389)和有既往根除治疗史患者(n = 148)的临床幽门螺杆菌分离株。无既往根除治疗史的患者中,幽门螺杆菌对克拉霉素和甲硝唑的耐药率分别为8.7%(95%CI,6.1 - 12)和13.8%(95%CI,10.4 - 17.3);有既往根除治疗史的患者中,耐药率分别为39.2%(95%CI,31.3 - 47.1)和37.8%(95%CI,30 - 45.7)(p<0.001)。克拉霉素耐药率保持稳定(1997年:9.7%;1998年:5.7%;1999年:11.8%;2000年:6.2%),而甲硝唑耐药率在4年研究期间有所下降(1997年:38.7%;1998年:15.1%;1999年:9%;2000年:6.9%)。我们未观察到耐药率变化与年度抗生素消耗量之间存在任何明确关系。
在我们所在的地理区域,克拉霉素的原发性耐药率保持稳定,而甲硝唑的耐药率在4年期间有所下降。